JPWO2023281007A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023281007A5
JPWO2023281007A5 JP2024500258A JP2024500258A JPWO2023281007A5 JP WO2023281007 A5 JPWO2023281007 A5 JP WO2023281007A5 JP 2024500258 A JP2024500258 A JP 2024500258A JP 2024500258 A JP2024500258 A JP 2024500258A JP WO2023281007 A5 JPWO2023281007 A5 JP WO2023281007A5
Authority
JP
Japan
Prior art keywords
refractory
multiple myeloma
pharmaceutical formulation
stem cell
lenalidomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524552A (ja
Publication date
Priority claimed from GBGB2109894.2A external-priority patent/GB202109894D0/en
Priority claimed from GBGB2112976.2A external-priority patent/GB202112976D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/068974 external-priority patent/WO2023281007A1/en
Publication of JP2024524552A publication Critical patent/JP2024524552A/ja
Publication of JPWO2023281007A5 publication Critical patent/JPWO2023281007A5/ja
Pending legal-status Critical Current

Links

JP2024500258A 2021-07-08 2022-07-07 多発性骨髄腫の治療に使用するためのメルフルフェン Pending JP2024524552A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2109894.2 2021-07-08
GBGB2109894.2A GB202109894D0 (en) 2021-07-08 2021-07-08 Novel treatments
GB2112976.2 2021-09-10
GBGB2112976.2A GB202112976D0 (en) 2021-09-10 2021-09-10 Novel treatments
PCT/EP2022/068974 WO2023281007A1 (en) 2021-07-08 2022-07-07 Melflufen for use in the treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
JP2024524552A JP2024524552A (ja) 2024-07-05
JPWO2023281007A5 true JPWO2023281007A5 (enExample) 2025-07-10

Family

ID=82702963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500258A Pending JP2024524552A (ja) 2021-07-08 2022-07-07 多発性骨髄腫の治療に使用するためのメルフルフェン

Country Status (5)

Country Link
US (1) US20240307480A1 (enExample)
EP (1) EP4366721A1 (enExample)
JP (1) JP2024524552A (enExample)
TW (1) TW202317084A (enExample)
WO (1) WO2023281007A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024121349A1 (en) * 2022-12-08 2024-06-13 Oncopeptides Ab Therapeutic treatment for haematological cancer based on the level of t-cell function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
HUE037863T2 (hu) 2011-04-28 2018-09-28 Oncopeptides Ab Citotoxikus dipeptidek liofilizált készítménye
BR112015009280B1 (pt) 2012-10-26 2022-05-31 Oncopeptides Ab Preparação farmacêutica liofilizada de melfalana flufenamida, composição e kit de combinação de partes
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
MA53904A (fr) 2018-10-18 2021-08-25 Oncopeptides Ab Composés contenant du deutérium
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations

Similar Documents

Publication Publication Date Title
AU2006332677B2 (en) Methods for treating cutaneous lupus using aminoisoindoline compounds
JP7445893B2 (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
JP2020172502A5 (enExample)
CN105050624A (zh) 利用阿普斯特来治疗银屑病关节炎的方法
JP2017525713A5 (enExample)
US11446314B2 (en) Immunoablative therapies
JP6906564B2 (ja) 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤
CN112839658A (zh) 用于治疗癌症的组合疗法
JP2023510309A (ja) 持続的免疫療法
JP2011016851A (ja) 免疫寛容を誘導するためのジアミド誘導体と免疫抑制剤との組み合わせ
KR20240142500A (ko) Psma-표적화 방사성제약 및 체크포인트 억제제 조합 요법
JPWO2023281007A5 (enExample)
AU2022214268A1 (en) Methods of treatment with s1p receptor modulators
JP2021505545A (ja) 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法
AU2021424131A1 (en) Methods of treatment with s1p receptor modulators
Alia biological treatment options of multiple myeloma
WO2012110200A1 (en) Cyclic peptide cyclo (l -arginyl - glycyl - l -aspartyl - d - phenylalanyl - n-methyl - l -valyl), compositions thereof, and use thereof in methods for treating graft -versus - host disease
WO2022016231A1 (en) Methods of treatment
TW202430160A (zh) 投予貝魯舒地爾（ｂｅｌｕｍｏｓｕｄｉｌ）治療多發性骨髓瘤之方法
Chaba et al. The Puzzle of Immunosuppressive Drugs
TW202120092A (zh) 化合物用於預防或治療移植物抗宿主病的用途
JP2025503213A (ja) Ｎｔｓｒ１標的化放射性医薬品およびチェックポイント阻害剤併用療法
CN101389330A (zh) 采用氨基异吲哚啉化合物治疗皮肤狼疮的方法
Sequeira Central nervous system stimulants and drugs that suppress appetite
Chen et al. Highlights in Graft-vs-Host Disease From the 2021 Transplantation & Cellular Therapy (TCT) Meetings of the ASTCT and the CIBMTR